University of Illinois Chicago, Chicago, IL 60607, USA.
Department of Surgery, University of Illinois College of Medicine, Peoria, IL 61605, USA.
Ther Deliv. 2024;15(11):829-843. doi: 10.1080/20415990.2024.2406226. Epub 2024 Oct 3.
EYP-1901 (Duravyu) has demonstrated promising outcomes in Phases I and II clinical trials for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)/diabetic retinopathy. This innovative treatment capitalizes on the potent anti-angiogenic properties of vorolanib, an inhibitor that targets all isoforms of VEGF, effectively mitigating the pathological neovascularization and vascular permeability that underpin these retinal conditions. EYP-1901 is integrated with the Durasert drug delivery system to administer a sustained release of vorolanib directly to the posterior segment of the eye. This delivery system ensures a consistent therapeutic effect over an extended period and significantly reduces the frequency of clinical interventions required, offering a more convenient treatment regimen while maintaining patient safety.
EYP-1901（杜拉鲁宾）在治疗新生血管性年龄相关性黄斑变性（nAMD）和糖尿病性黄斑水肿（DME）/糖尿病性视网膜病变的 I 期和 II 期临床试验中显示出了有前景的结果。这种创新的治疗方法利用了 vorolanib 的强大抗血管生成特性，vorolanib 是一种针对所有 VEGF 同工型的抑制剂，能够有效减轻这些视网膜疾病中潜在的病理性新生血管形成和血管通透性。EYP-1901 与 Durasert 药物输送系统相结合，可将 vorolanib 持续释放到眼睛的后段。这种输送系统可确保在较长时间内保持一致的治疗效果，并显著减少所需的临床干预次数，提供更方便的治疗方案，同时保持患者安全。
